![Anti-MHC II DR antibody [EBS-O-110] (STJ16101039)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/124x110/products/149755/302500/STJ16101039_1__65994.1646940671.jpg?c=1 "Anti-MHC II DR antibody [EBS-O-110] (STJ16101039)")
![Anti-MHC II DR antibody [EBS-O-110] (STJ16101039)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/1280x1280/products/149755/302500/STJ16101039_1__65994.1646940671.jpg?c=1 "Anti-MHC II DR antibody [EBS-O-110] (STJ16101039)")
Anti-MHC II DR antibody [EBS-O-110] (STJ16101039)
SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgG2bk
ImmunogenA C3H mouse was immunized with Human PBL and HLA-homozygous B-LCL line. Fusion partner: Sp2/0.
General Information
| Short Description | Mouse monoclonal anti-MHC II DR for use in FC, IF and IHC in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | FC/IF/IHC |
| Host | Mouse |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | EBS-O-110 |
| Isotype | IgG2bk |
| Conjugation | Unconjugated |
| Concentration | Can be provided as 100 µg/mL, 500 µg/mL or 1mg/mL. |
| Purification | Affinity purified from tissue culture. |
| Dilution Range | Flow cytometry (0, 5-1, 0 µg/million cells in 0, 1 ml). Immunofluorescence (0, 5-1, 0 µg/ml). Immunohistology (1-2 µg/ml for 30 min at RT; an appropriate antigen retrieval method for staining of formalin-fixed tissues has not been established to date |
| Formulation | PBS with 0.02% Sodium Azide. |
| Storage Instruction | Store for up to 1 year at 2-8°C upon receipt. |
Target Information
| Gene Symbol | HLA-DRB5 |
| Gene ID | 3127 |
| Uniprot ID | DRB5_HUMAN |
| Immunogen | A C3H mouse was immunized with Human PBL and HLA-homozygous B-LCL line. Fusion partner: Sp2/0. |
Additional Info
| Post Translational Modifications | Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to down-regulation of MHC class II. |
| Function | Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. |
| Protein Name | Hla Class Ii Histocompatibility Antigen - Dr Beta 5 ChainDr Beta-5Dr2-Beta-2Dw2Mhc Class Ii Antigen Drb5 |
| Database Links | Reactome: R-HSA-202424Reactome: R-HSA-202427Reactome: R-HSA-202430Reactome: R-HSA-202433Reactome: R-HSA-2132295Reactome: R-HSA-389948Reactome: R-HSA-877300 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinEndoplasmic Reticulum MembraneGolgi ApparatusTrans-Golgi Network MembraneEndosome MembraneLysosome MembraneLate Endosome MembraneThe Mhc Class Ii Complex Transits Through A Number Of Intracellular Compartments In The Endocytic Pathway Until It Reaches The Cell Membrane For Antigen Presentation |
| Alternative Antibody Names | Anti-Hla Class Ii Histocompatibility Antigen - Dr Beta 5 Chain antibodyAnti-Dr Beta-5 antibodyAnti-Dr2-Beta-2 antibodyAnti-Dw2 antibodyAnti-Mhc Class Ii Antigen Drb5 antibodyAnti-HLA-DRB5 antibody |
Information sourced from Uniprot.org